Evidence map›Paper›PMID 30543311›Full record

Trial reportOphthalmic epidemiology2019

Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.

Nana Wilson, Brook Goodhew, Harran Mkocha, Kahaliah Joseph, Claudiu Bandea, Carolyn Black, Joseph Igietseme, Beatriz Munoz, Sheila K West, Patrick Lammie and 2 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmic epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Antibiotics for trachoma.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Monitoring transmission intensity of trachoma with serology.medRxiv : the preprint server for health sciences · 2023
    Article
  8. Article
  9. Trachoma.Nature reviews. Disease primers · 2022
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Nana Wilsona Division of Parasitic Diseases and Malaria , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Brook Goodhewa Division of Parasitic Diseases and Malaria , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Harran Mkochab Kongwa Trachoma Project , Kongwa , Tanzania.
Kahaliah Josephc National Center for Emerging, Zoonotic, and Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Claudiu Bandeac National Center for Emerging, Zoonotic, and Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Carolyn Blackc National Center for Emerging, Zoonotic, and Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Joseph Igietsemec National Center for Emerging, Zoonotic, and Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Beatriz Munozd Wilmer Eye Institute, Johns Hopkins University , Baltimore , MD , USA.
Sheila K Westd Wilmer Eye Institute, Johns Hopkins University , Baltimore , MD , USA.
Patrick Lammiea Division of Parasitic Diseases and Malaria , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Mabula Kasubie Muhimbili University , Dar es Salaam , Tanzania.
Diana L Martina Division of Parasitic Diseases and Malaria , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Centers for Disease Control and Prevention · USJohns Hopkins University · USNational Center for Emerging and Zoonotic Infectious Diseases · USDivision of Parasitic Diseases and Malaria · USMuhimbili University of Health and Allied Sciences · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTrachoma, caused by repeated ocular infection with Chlamydia trachomatis, is the leading infectious cause of blindness worldwide and is targeted for elimination as a public health problem. We sought to determine whether a one-time azithromycin mass treatment would reduce trachomatous inflammation-follicular (TF) levels below the elimination threshold of 5% in communities with disease prevalence between 5 and 9.9%.

methodsThe study was conducted in 96 sub-village units (balozis) in the Kongwa district of Tanzania which were predicted from prior prevalence surveys to have TF between 5 and 9.9%. Balozis were randomly assigned to the intervention and control arms. The intervention arm received a single mass drug administration of azithromycin. At baseline and 12-month follow-up, ocular exams for trachoma, ocular swabs for detection of chlamydial DNA, and finger prick blood for analysis of anti-chlamydial antibody were taken.

resultsComparison of baseline and 12-month follow-up showed no significant difference in the overall TF

conclusionThese data suggest that a single round of MDA may not be sufficient to decrease TF levels below 5% when TF

Indexed as

Anti-Bacterial AgentsAzithromycinChildChild, PreschoolChlamydia trachomatisDNA, BacterialDose-Response Relationship, DrugEye Infections, BacterialFemaleFollow-Up StudiesHumansInfantMalePrevalenceTanzaniaTime FactorsAnti-Bacterial AgentsAzithromycinDNA, BacterialAntibodychlamydiamass drug administrationtrachomatrachomatis

Identifiers

PMID30543311
PMCPMC6352373
OpenAlexW2904086932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.